Bank of New York Mellon Corp - INHIBIKASE THERAPEUTICS INC ownership

INHIBIKASE THERAPEUTICS INC's ticker is IKT and the CUSIP is 45719W106. A total of 20 filers reported holding INHIBIKASE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of INHIBIKASE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$25,651
+31.5%
39,0070.0%0.00%
Q4 2022$19,504
-45.8%
39,007
-0.8%
0.00%
Q3 2022$36,000
+24.1%
39,3120.0%0.00%
Q2 2022$29,000
-50.8%
39,312
-0.7%
0.00%
Q1 2022$59,000
+1.7%
39,5800.0%0.00%
Q4 2021$58,000
-22.7%
39,5800.0%0.00%
Q3 2021$75,00039,5800.00%
Other shareholders
INHIBIKASE THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
ACT CAPITAL MANAGEMENT, LLC 937,500$696,0000.97%
HAMILTON LANE ADVISORS LLC 165,635$123,0000.05%
Redmond Asset Management, LLC 122,682$91,0000.03%
Retirement Planning Co of New England, Inc. 64,606$47,0000.03%
Antara Capital LP 403,000$299,0000.01%
ZEKE CAPITAL ADVISORS, LLC 93,800$70,0000.01%
Koshinski Asset Management, Inc. 65,377$49,0000.01%
K.J. Harrison & Partners Inc 18,300$14,0000.00%
Warberg Asset Management LLC 14,493$11,0000.00%
Shay Capital LLC 10,708$8,0000.00%
View complete list of INHIBIKASE THERAPEUTICS INC shareholders